Rights and permissions
About this article
Cite this article
Imatinib mesylate vs allografting in CML: residual disease. Inpharma Wkly. 1409, 15 (2003). https://doi.org/10.2165/00128413-200314090-00033
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200314090-00033